100 related articles for article (PubMed ID: 3424288)
1. A novel, stable high molecular weight urokinase: preliminary results.
Grabenwoeger F; Duma S; Dock W
Thromb Res; 1987 Oct; 48(2):173-8. PubMed ID: 3424288
[TBL] [Abstract][Full Text] [Related]
2. [Thrombolytic agents].
Furukawa K
Nihon Geka Gakkai Zasshi; 1984 Sep; 85(9):1166-9. PubMed ID: 6503980
[TBL] [Abstract][Full Text] [Related]
3. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
[TBL] [Abstract][Full Text] [Related]
4. Synergism of thrombolytic agents in vivo.
Collen D; Stassen JM; Stump DC; Verstraete M
Circulation; 1986 Oct; 74(4):838-42. PubMed ID: 3093116
[TBL] [Abstract][Full Text] [Related]
5. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
Korninger C; Matsuo O; Suy R; Stassen JM; Collen D
J Clin Invest; 1982 Mar; 69(3):573-80. PubMed ID: 7199539
[TBL] [Abstract][Full Text] [Related]
6. Increase in the degree of phosphorylation of circulating fibrinogen under thrombolytic therapy with urokinase.
Seydewitz HH; Matthias FR; Schöndorf TH; Witt I
Thromb Res; 1987 May; 46(3):437-45. PubMed ID: 3603434
[TBL] [Abstract][Full Text] [Related]
7. Does thrombolytic therapy have a place in the treatment of pulmonary embolism after the acute stage?
Brochier M; Griguer P; Raynaud P; Charbonnier B; Desveaux B; François G
Haemostasis; 1986; 16 Suppl 3():58-64. PubMed ID: 3770545
[No Abstract] [Full Text] [Related]
8. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound-enhanced Thrombolysis.
Motarjeme A
J Endovasc Ther; 2007 Apr; 14(2):251-6. PubMed ID: 17484537
[TBL] [Abstract][Full Text] [Related]
10. [Acyl enzymes and pro-urokinase: promising new thrombolytic agents].
Samama M; Horellou MH; Nguyen G; Conard J
Haemostasis; 1986; 16 Suppl 4():35-9. PubMed ID: 3095199
[No Abstract] [Full Text] [Related]
11. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G
Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic application of contrast-enhanced ultrasound and low-dose urokinase for thrombolysis in a porcine model of acute peripheral arterial occlusion.
Ebben HP; Nederhoed JH; Slikkerveer J; Kamp O; Tangelder GW; Musters RJ; Wisselink W; Yeung KK
J Vasc Surg; 2015 Aug; 62(2):477-85. PubMed ID: 24768365
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic therapy for femoral artery thrombosis after left cardiac catheterization in children.
Liu Q; Yan CW; Zhao SH; Jiang SL; Xu ZY; Huang LJ; Ling J; Zheng H; Wang Y
Chin Med J (Engl); 2009 Apr; 122(8):931-4. PubMed ID: 19493417
[TBL] [Abstract][Full Text] [Related]
14. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
Gurewich V
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):16B-21B. PubMed ID: 3117859
[TBL] [Abstract][Full Text] [Related]
15. Nonrandomized comparison of local urokinase thrombolysis versus systemic heparin anticoagulation for superior sagittal sinus thrombosis.
Wasay M; Bakshi R; Kojan S; Bobustuc G; Dubey N; Unwin DH
Stroke; 2001 Oct; 32(10):2310-7. PubMed ID: 11588319
[TBL] [Abstract][Full Text] [Related]
16. Local intra-arterial fibrinolysis in acute hemispheric stroke: effect of occlusion type and fibrinolytic agent on recanalization success and neurological outcome.
Eckert B; Kucinski T; Neumaier-Probst E; Fiehler J; Röther J; Zeumer H
Cerebrovasc Dis; 2003; 15(4):258-63. PubMed ID: 12686789
[TBL] [Abstract][Full Text] [Related]
17. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
[TBL] [Abstract][Full Text] [Related]
18. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
19. Clot-selective coronary thrombolysis with pro-urokinase.
Loscalzo J; Wharton TP; Kirshenbaum JM; Levine HJ; Flaherty JT; Topol EJ; Ramaswamy K; Kosowsky BD; Salem DN; Ganz P
Circulation; 1989 Apr; 79(4):776-82. PubMed ID: 2494004
[TBL] [Abstract][Full Text] [Related]
20. alpha 2-Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy.
Collen D; Verstraete M
Thromb Res; 1979; 14(4-5):631-9. PubMed ID: 90396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
